Respiratory syncytial virus (RSV) often presents with mild symptoms in healthy individuals. However, in older adults or infants RSV infection can have serious complications. Adding to the burden, people can become infected with RSV multiple times throughout their lifetime. Research on RSV vaccines is robust, with one candidate recently receiving Breakthrough Therapy Designation. With such rapid and novel developments, it is important for healthcare providers to stay current on the evolving research and management strategies. In this interactive video lecture, an infectious disease specialist details the impact of RSV on different patient populations, reviews currently available and emerging options, and provides valuable information to share with your patients
Interactive video lecture
After completing this activity, participants should be better able to:
- Explain the risk factors, impact, and potential complications of RSV in older adults
- Summarize clinical trial evidence of the efficacy and safety of investigational RSV vaccines
- Design strategies to address barriers to vaccination and increase vaccine uptake
NPs and PAs
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Mary D. Knudtson, DNSc, NP, FAAN, University of California, Irvine, Irvine, California
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until September 29, 2022. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program was cosupported by educational grants from Janssen Therapeutics, Division of Janssen Products, LP and Seqirus USA Inc.
This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Piparo has no relevant financial relationships to disclose.
Dr Zivin-Tutela has no relevant financial relationships to disclose.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the evaluation form
The estimated time to complete this activity is 1.00 hour.
Release date: September 30, 2021
Expiration date: September 29, 2022
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 102821VAC-7B